Evaluation of conflict of interest in economic analyses of new drugs used in oncology.
about
Ban on Dextropropoxyphene is UnjustifiableBias in published cost effectiveness studies: systematic review.Authors' financial relationships with the food and beverage industry and their published positions on the fat substitute olestraRelationship between conflicts of interest and research resultsPharmaceutical industry sponsorship and research outcome and quality: systematic reviewMaterializing research promises: opportunities, priorities and conflicts in translational medicineReporting of conflicts of interest in guidelines of preventive and therapeutic interventionsFunding source, trial outcome and reporting quality: are they related? Results of a pilot studyThe benefits and threats of research partnerships with industryThe Effect of Calcium Sodium Phosphosilicate on Dentin Hypersensitivity: A Systematic Review and Meta-AnalysisAntidepressants and breast and ovarian cancer risk: a review of the literature and researchers' financial associations with industryPublic welfare agenda or corporate research agenda?Research accountability and financial conflicts of interest in industry-sponsored clinical research: a review.Prevalence of industry support and its relationship to research integrityTen steps to developing a national agenda to address financial conflicts of interest in industry sponsored clinical research.The fading of reported effectiveness. A meta-analysis of randomised controlled trials.HEE-GER: a systematic review of German economic evaluations of health care published 1990-2004Characteristics associated with citation rate of the medical literature.Comparing estimates of cost effectiveness submitted to the National Institute for Clinical Excellence (NICE) by different organisations: retrospective study.Alteplase for stroke: money and optimistic claims buttress the "brain attack" campaign.Efficacy, safety, and cost of new anticancer drugs.Efficacy, safety, and cost of new anticancer drugs. Pessimistic conclusion was not justified.Dancing with the porcupine: rules for governing the university-industry relationshipThe contract research organization and the commercialization of scientific research.The status of clinical trials: cause for concern.Taking financial relationships into account when assessing research.Association between pharmaceutical support and basic science research on erythropoiesis-stimulating agentsCost-effectiveness analysis for cliniciansCoauthorship and institutional collaborations on cost-effectiveness analyses: a systematic network analysisDrug policy down under: Australia's pharmaceutical benefits scheme.Reporting of serious adverse events during cancer clinical trials to the institutional review board: an evaluation by the research on adverse drug events and reports (RADAR) project.Aromatase inhibitors for breast cancer: pharmacoeconomic considerations.Conflict of interest in spine research reporting.What affects the quality of economic analysis for life-saving investments?Relationships between authorship contributions and authors' industry financial ties among oncology clinical trials.How NICE may be outflanked.Do coxibs reduce prescription of gastroprotective agents? Results of a record linkage study.Industry involvement and baseline assumptions of cost-effectiveness analyses: diagnostic accuracy of the Papanicolaou test.Science and money: problems and solutions.When are statins cost-effective in cardiovascular prevention? A systematic review of sponsorship bias and conclusions in economic evaluations of statins.
P2860
Q24273327-BDB014B8-A525-49E2-931D-AF9EA6854CA1Q24541365-434E871C-55E7-4E83-8544-732E7A2ACAF6Q24544340-81D734DC-EF77-486F-BF48-6488E1ABC6FEQ24550578-4711A607-933B-4182-A61D-2889401DDBEBQ24673248-55A37DC4-16A4-43DC-90DA-BAC7870D6FDFQ24797709-B91DEA88-AE8E-4C35-9BCB-F487D4174D27Q24799693-CBCF9E74-FCBA-4749-8062-D6430BD6F0D4Q24802299-64C964A7-A2EC-4E67-8AA4-8AC286F51B1DQ24810516-59F087B8-0136-49A1-89E9-F674EFE8B8D9Q26778640-0AA25E98-CF70-427A-B1A6-517DDC5C440FQ28477668-6733B5D5-5425-489A-AEB7-ECFC1EB93C77Q28728749-3F811844-99ED-4861-BD29-E5E4177B0A2FQ30433010-B77056D6-D94B-47CA-98F5-3A0252DF7FABQ30438220-68015A83-D7BD-4173-BDE7-1004BB6EB785Q30438344-12D215C3-5CC0-49D4-9E18-93E1BFA6FBB9Q30814884-188D79BC-4624-448C-B16B-6A3D5B36D921Q33269184-7498ED37-92D1-40F8-A1B4-4B86C7DEFA01Q33283512-291AA6C6-1B27-4FD7-9E14-A6CA573BD23EQ33709566-485C6C9A-9A16-479F-9276-1ACFE3CEBA89Q33809694-09CB342F-72E2-4BF2-8655-3172075E9798Q33811454-73A77C8F-9358-4B5F-8A16-843DE9384096Q33813161-14CB8FCF-6F23-4DB1-87BE-85A513B93DFFQ33956540-C0DAE409-473E-4697-AABE-18736C0FF17FQ33991605-0420BBB5-14BA-475A-9DDC-C18D6CF221A8Q34008551-D2ABAB46-D9C2-4915-996A-313929A69CEAQ34036715-1DF49DD6-ED67-4D42-B2EB-6B1B2221870DQ34068226-6403A967-2D80-41CC-9E9F-00491C802486Q34148072-63677D5F-EEDF-45D6-AA25-14A5358A56F5Q34292774-794D4244-05D9-4435-B5EA-591D8F9E6C43Q34328049-18AD525C-BEB9-459C-BF04-3EB9F1A7AF4AQ34370603-3EE9BD5B-E8AF-46CB-9905-1AF8C284664BQ34390312-53E0531D-59C5-48DE-9C9A-BA2AD3C5D2ECQ34406597-99A34685-A619-4DC8-B09F-27BFC8905A65Q34546567-4B178571-F9F0-4F04-B624-34E775565E05Q34578579-4F02B73D-E42E-49EB-BBA9-51E5824EDE7BQ34647243-144E3107-9BCA-4FF4-9310-5516C986EDA1Q34666402-BC773BA9-7027-4D33-831D-5F4F4535FBE9Q34765264-3CC6B74A-C856-4ED5-B267-DA7C2DC7B2D4Q34781966-BE4195B0-E089-4DB2-B90F-CFE2C75EDFB5Q34828582-24B6DC68-CFC3-4BB0-8A3C-78D092EF0659
P2860
Evaluation of conflict of interest in economic analyses of new drugs used in oncology.
description
1999 nî lūn-bûn
@nan
1999 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Evaluation of conflict of interest in economic analyses of new drugs used in oncology.
@ast
Evaluation of conflict of interest in economic analyses of new drugs used in oncology.
@en
type
label
Evaluation of conflict of interest in economic analyses of new drugs used in oncology.
@ast
Evaluation of conflict of interest in economic analyses of new drugs used in oncology.
@en
prefLabel
Evaluation of conflict of interest in economic analyses of new drugs used in oncology.
@ast
Evaluation of conflict of interest in economic analyses of new drugs used in oncology.
@en
P2093
P356
P1476
Evaluation of conflict of interest in economic analyses of new drugs used in oncology.
@en
P2093
C L Bennett
M Friedberg
T J Stinson
P304
P356
10.1001/JAMA.282.15.1453
P407
P577
1999-10-01T00:00:00Z